<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor IX, recombinant human glycopegylated: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor IX, recombinant human glycopegylated: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor IX, recombinant human glycopegylated: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="113444" href="/d/html/113444.html" rel="external">see "Factor IX, recombinant human glycopegylated: Drug information"</a> and <a class="drug drug_patient" data-topicid="113709" href="/d/html/113709.html" rel="external">see "Factor IX, recombinant human glycopegylated: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50810516"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rebinyn</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872284"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rebinyn</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F57941070"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F50771542"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Contains <b>only factor IX</b>. Therefore, <b>NOT INDICATED</b> for the treatment of other factor deficiencies (eg, factors II, VII, VIII, X), hemophilia A with inhibitors to factor VIII, reversal of coumarin-induced anticoagulation, and bleeding due to low levels of liver-dependent clotting factors.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d3c8dbc-ec3d-4b92-8b0e-9f550b04753f">Hemophilia B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B (congenital factor IX deficiency): Note:</b> Individualize dosage based on clinical response and factor IX activity evaluated at baseline and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control and prevention of bleeding episodes or perioperative management: Note: </b>Dosage is expressed in units of factor IX activity and must be individualized based on severity of factor IX deficiency, extent and location of bleed, individualized incremental recovery using factor IX activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Utilize steps 1 through 4 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Identify product-specific in vivo recovery (IVR) for dosing calculations. <b>Note:</b> IVR indicates the expected increase in factor IX level, which occurs with 1 unit/kg of factor IX product administration:</p>
<p style="text-indent:-2em;margin-left:10em;">Rebinyn IVR: <b>Note:</b> IVR data for ages ≤12 years is based on a single dose; IVR data for ages ≥13 years is based on steady-state dose data.</p>
<p style="text-indent:-2em;margin-left:12em;">≤6 years: 1.51 units/dL per units/kg</p>
<p style="text-indent:-2em;margin-left:12em;">7 to 12 years: 1.59 units/dL per units/kg</p>
<p style="text-indent:-2em;margin-left:12em;">13 to 17 years: 1.82 units/dL per units/kg</p>
<p style="text-indent:-2em;margin-left:12em;">≥18 years: 1.92 units/dL per units/kg</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Determine desired factor IX peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. These recommendations reflect WFH guidelines for higher-dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference (WFH [Srivastava 2020]).</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption style="text-align:left;">
<b>WFH Treatment Recommendations<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Desired Factor IX Peak Level</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Duration</b>
<sup>b</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>(WFH [Srivastava 2020]).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>b</sup> Depending on procedure; the number of doses would depend on the half-life of the clotting factor concentrate used.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>c</sup> May be longer if response is inadequate.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>d</sup> A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>e </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Joint</p></td>
<td align="left">
<p style="text-indent:0em;">40 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 2 days<sup>c,d</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="left">
<p style="text-indent:0em;">40 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">2 to 3 days<sup>c</sup></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Iliopsoas or deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="left">
<p style="text-indent:0em;">Initial: 60 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 2 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Maintenance: 30 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 5 days<sup>e</sup></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="left">
<p style="text-indent:0em;">Initial: 60 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 7 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Maintenance: 30 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">8 to 21 days</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="left">
<p style="text-indent:0em;">Initial: 60 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 7 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Maintenance: 30 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">8 to 14 days</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">GI</p></td>
<td align="left">
<p style="text-indent:0em;">Initial: 60 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">7 to 14 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Maintenance: 30 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Not specified</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Renal</p></td>
<td align="left">
<p style="text-indent:0em;">40 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="left">
<p style="text-indent:0em;">40 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="left">
<p style="text-indent:0em;">Pre-op: 60 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Post-op: 40 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 3 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Post-op: 30 to 50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">4 to 6 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Post-op: 20 to 40 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">7 to 14 days</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="left">
<p style="text-indent:0em;">Pre-op: 50 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Post-op: 30 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 5 days</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Calculate dose using IVR from step 1, desired peak factor IX level from step 2, and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = ([desired peak factor IX level − patient's baseline factor IX level] × body weight [kg])/IVR</p>
<p style="text-indent:-2em;margin-left:10em;">Example (Rebinyn) for 5-year-old patient weighing 20 kg with a desired peak factor IX level of 35 units/dL, baseline factor IX level of 5 units/dL, IVR = 1.51:</p>
<p style="text-indent:-2em;margin-left:12em;">Factor IX units required = ([35 units/dL − 5 units/dL] × 20 kg) ⁄ 1.51 = 397 units factor IX</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 4: </b>Frequency of repeat dosing is based on half-life of product used (see product-specific labeling for details), type of bleed or surgery, and patient response. If subsequent factor IX levels are available for individual patients, these should be taken into consideration when determining the frequency of repeat doses.</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption style="text-align:left;">
<b>Factor IX Recombinant Glycopegylated Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left" rowspan="2">
<p style="text-indent:0em;">
<b>Product</b></p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">
<b>Bleeding event</b></p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">
<b>Surgery</b></p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Minor Severity<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Moderate Severity<sup>b</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Major Severity<sup>c</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minor Bleeding Risk<sup>d</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Major Bleeding Risk<sup>e</sup></b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>a</sup> Minor bleeds include early hemarthrosis, mild muscle bleeding, or mild oral bleeding episode.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>b</sup> Moderate bleeds include muscle bleeding, moderate bleeding into the oral cavity, definite hemarthroses, and known trauma.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>c</sup> Major bleeds include significant GI bleeding, intracranial, intra-abdominal or intrathoracic bleeding, CNS bleeding, bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath, fractures, head trauma.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>d</sup> Including tooth extraction.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>e</sup> For example, intracranial, intra-abdominal, or intrathoracic surgery, joint replacement surgery.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Rebinyn</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose is typically adequate. Additional doses can be given if needed. Due to prolonged half-life, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose is typically adequate. Additional doses can be considered. Due to prolonged half-life, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose is typically adequate. Additional doses can be considered. Due to prolonged half-life, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="left">
<p style="text-indent:0em;">Single preoperative dose is typically adequate. Additional doses can be given if needed. Due to prolonged half-life, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="left">
<p style="text-indent:0em;">Every 1 to 3 days based on response and factor IX levels. After the first week, dosing frequency may be extended to once weekly.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis to reduce the frequency of bleeding episodes: Note:</b> Maintain trough factor IX levels &gt;3% to 5% or higher as clinically indicated based on level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 40 units/kg/dose once weekly; adjust dose or frequency based on patient's clinical response.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109870"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels.</p></div>
<div class="block dohp drugH1Div" id="F51109871"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>
<div class="block doa drugH1Div" id="F50770564"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="113444" href="/d/html/113444.html" rel="external">see "Factor IX, recombinant human glycopegylated: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98495059-e110-44f0-ad91-ba0bd4d84e5d">Hemophilia B, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Contains <b>only factor IX.</b> Therefore, <b>NOT INDICATED</b> for replacement therapy of other clotting factors besides factor IX, hemophilia A patients with inhibitors to factor VIII, reversal of anticoagulation due to vitamin K antagonists or other anticoagulants, or bleeding due to low levels of liver-dependent clotting factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing: </i>IV:</b> Utilize steps 1 to 4 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Identify product-specific in vivo recovery (IVR) for dosing calculations (<b>Note:</b> IVR indicates the expected increase in factor IX level, which occurs with 1 unit/kg of factor IX product administration):</p>
<p style="text-indent:-2em;margin-left:10em;">Rebinyn IVR: 1.9.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Determine desired factor IX peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Factor IX </b>
<b>(Recombinant Glycopegylated) WFH Treatment Recommendations<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Type of hemorrhage or surgery</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Lower dose practice pattern</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Higher dose practice pattern</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;">Treatment duration (days)</p></th>
<th align="center">
<p style="text-indent:0em;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;">Treatment duration (days)</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>WFH = World Federation of Hemophilia; (WFH [Srivastava 2020]).</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> May be longer if response is inadequate.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,d</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,d</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>c</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and neck</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>GI</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 70</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Calculate dose using IVR from step 1, desired peak factor IX level from step 2, and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = ([desired peak factor IX level − patient's baseline factor IX level] × body weight [kg])/IVR</p>
<p style="text-indent:-2em;margin-left:12em;">(<b>Note:</b> Factor IX units are in units/dL.)</p>
<p style="text-indent:-2em;margin-left:10em;">Example (Rebinyn) for 50 kg patient with desired peak factor IX level of 35 units/dL, baseline factor IX level of 5 units/dL, IVR = 1.9:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = ([35 units/dL − 5 units/dL] × 50 kg) ⁄ 1.9 = 789 units factor IX</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 4:</b> Determine need for repeat dosing based on manufacturer’s recommended frequency of repeat dosing. <b>Note</b>
<b>:</b> Frequency of administration must also take into consideration subsequent factor IX activity measurements and clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Factor IX (Recombinant Glycopegylated) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">Bleeding event</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="center">
<p style="text-indent:0em;">Major severity</p></th>
<th align="center">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="center">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Rebinyn</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Single dose is typically adequate. Additional doses can be given if needed. Due to prolonged half-life of ~115 hours, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Single dose is typically adequate. Additional doses can be considered. Due to prolonged half-life of ~115 hours, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Single dose is typically adequate. Additional doses can be considered. Due to prolonged half-life of ~115 hours, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Single preoperative dose is typically adequate. Additional doses can be given if needed. Due to prolonged half-life of ~115 hours, base timing of redosing on serial factor IX level measurements.</p></td>
<td align="center">
<p style="text-indent:0em;">Every 1 to 3 days based on response and factor IX levels. After the first week, dosing frequency may be extended to once weekly.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with moderate/severe hemophilia B without inhibitors</i></b>
<b>
<i>:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 40 units/kg once weekly; may titrate dose or frequency based on patient's clinical response. Dosing should be tailored to ensure trough factor IX levels of ≥1% and preferably ≥3% to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (WFH [Srivastava 2020]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990760"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels.</p></div>
<div class="block doha drugH1Div" id="F50987776"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>
<div class="block adr drugH1Div" id="F50306490"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in pediatric patients and adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Dermatologic: Skin rash (infants and children: 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Factor IX inhibitor in hemophilia B (infants and children: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (infants and children: 2%), hypersensitivity reaction (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (2% to 4%)</p></div>
<div class="block coi drugH1Div" id="F50169223"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to factor IX (recombinant [glycopegylated]), hamster protein, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F50723032"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Allergic-type hypersensitivity reactions, including anaphylaxis, may occur. Observe patients for signs/symptoms of acute hypersensitivity reactions, particularly during the initial exposure. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors. If hypersensitivity reactions occur, discontinue immediately; in the case of severe allergic reactions, consider the use of alternative hemostatic measures (WFH [Srivastava 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotic syndrome: Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions. Safety and efficacy in this situation have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Observe closely for signs or symptoms of intravascular coagulation or thrombosis; risk is generally associated with the use of factor IX complex concentrates (containing therapeutic amounts of additional factors); however, potential risk exists with use of factor IX products (containing only factor IX). Use with caution when administering to patients with liver disease, postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the increased risk of thromboembolic complications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hamster protein: May contain trace amounts of Chinese hamster proteins; hypersensitivity to these proteins may develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F57941097"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In animal toxicity studies, repeated doses of factor IX (recombinant [glycopegylated]) led to accumulation of polyethylene glycol in parts of the CNS. The clinical implications of this finding are unknown. Pediatric studies have followed patients for up to 8 years' duration, and no clear clinical neurologic/neurocognitive safety signals have been observed; however, prescribers should be aware of the potential risks in patients who are at risk for cognitive impairment (infants and children who have developing brains and patients with cognitive impairment). Also consider factors that can increase the risk for neurologic adverse effects such as duration, cumulative dose, patient age, and patient comorbidities.</p></div>
<div class="block foc drugH1Div" id="F50810517"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rebinyn: 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea) [pyrogen free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rebinyn: 3000 units (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F50723028"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51083810"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Rebinyn Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $5.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $5.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $5.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (per each): $5.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872285"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rebinyn: 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52622700"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV infusion only. Solution should be infused at room temperature. Infuse slowly over 1 to 4 minutes based on patient response and comfort.</p></div>
<div class="block adm drugH1Div" id="F50723047"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV infusion only. Solution should be infused at room temperature. Infuse slowly over 1 to 4 minutes based on patient response and comfort.</p></div>
<div class="block sts drugH1Div" id="F50723034"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F) in the original packaging for ≤24 months from the date of manufacture until the expiration date stated on the label. Protect from light; do not freeze. May be stored at room temperature ≤30°C (86°F) for ≤6 months within the 24-month time period. Do not return to the refrigerator. Do not use after the end of the 6-month period at room temperature storage, or after the expiration date stated on the vial, whichever occurs earlier. Use within 4 hours after reconstitution when stored at room temperature; discard any unused product.</p></div>
<div class="block usep drugH1Div" id="F57941080"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hemophilia B (congenital factor IX deficiency) as either on-demand treatment and control of bleeding episodes, perioperative management of or routine prophylaxis to reduce the frequency of bleeding episodes (All indications: FDA approved in ages ≥1 year and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Products contain only factor IX. These products are NOT INDICATED for the treatment of other factor deficiencies (eg, factor II, VII, VIII, X), for the treatment of hemophilia A with inhibitors to factor VIII, for the reversal of coumarin-induced anticoagulation, for the treatment of bleeding because of low levels of liver-dependent coagulation factors, or for induction of immune tolerance in patients with hemophilia B.</p></div>
<div class="block mst drugH1Div" id="F50723026"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor IX may be confused with Factor IX Complex</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50305480"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50305477"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F50723030"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant carriers of hemophilia B may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor IX levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor IX levels remain stable during pregnancy, factor IX replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor IX concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If replacement with a factor IX concentrate is indicated to increase factor IX during pregnancy, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block mopp drugH1Div" id="F57945554"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Factor IX levels by chromogenic FIX assay or an aPTT-based one-stage factor IX activity assay with validated reagents, calibrated with a plasma standard traceable to a WHO international standard. <b>Note:</b> Most one-stage FIX assays significantly overestimate or underestimate Rebinyn FIX activity and should not be used. One-stage assays using the ellagic acid activator reagent SynthAFax or the polyphenol activator reagent Cephascreen are suitable for monitoring Rebinyn therapy (WFH [Srivastava 2020]). Monitor for signs and symptoms of hypersensitivity reactions, disseminated intravascular coagulation, and thrombosis. Screen for factor IX inhibitors if the patient experiences a hypersensitivity reaction, if suboptimal response to treatment occurs, or after recurrent bleeds despite adequate factor IX replacement; all patients should have factor IX inhibitors screened every 6 to 12 months after therapy is initiated and then annually (WFH [Srivastava 2020]).</p></div>
<div class="block rerp drugH1Div" id="F57945555"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Classification of hemophilia (WFH [Srivastava 2020]):</p>
<p style="text-indent:-2em;margin-left:4em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F50723036"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa) in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis. Factor IX is conjugated to a 40-kDa polyethylene glycol molecule, which slows down its removal from the circulation.</p></div>
<div class="block phk drugH1Div" id="F50723039"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single dose</i>: V<sub>d</sub>: Children ≤6 years of age: 72.3 mL/kg; Children 7 to 12 years: 68.3 mL/kg; Adolescents 13 to 17 years: 58.6 mL/kg; Adults: 47 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>After multiple once-weekly prophylactic doses (steady state)</i>: V<sub>dss</sub>: Adolescents 13 to 17 years: 60.5 mL/kg; Adults: 65.8 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single dose:</i> Children ≤6 years of age: 69.6 hours; Children 7 to 12 years: 76.3 hours; Adolescents 13 to 17 years: 89.4 hours; Adults: 83 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>After multiple once-weekly prophylactic doses (steady state)</i>: Adolescents 13 to 17 years: 103.1 hours; Adults: 114.9 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58214285"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rebinyn</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Refixia</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation. MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). 2007. http://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis.</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rebinyn.1">
<a name="Rebinyn.1"></a>Rebinyn (factor IX [recombinant (glycopegylated)]) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15384973">
<a name="15384973"></a>Srivastava A. Dose and response in haemophilia--optimization of factor replacement therapy. <i>Br J Haematol</i>. 2004;127(1):12-25. doi: 10.1111/j.1365-2141.2004.05110.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-glycopegylated-pediatric-drug-information/abstract-text/15384973/pubmed" id="15384973" target="_blank">15384973</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141024 Version 12.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
